DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.
REFERENCES
  1. Park JR, Kreissman SG, London WB, et al. Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial. JAMA . 2019;322:746-755.
  2. Ladenstein R, Pötschger U, Pearson ADJ, et al; SIOP Europe Neuroblastoma Group (SIOPEN). Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. Lancet Oncol . 2017;18:500-514.
  3. Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children’s oncology group study. J Clin Oncol. 2009;27:1007-1013.
  4. Valteau-Couanet D, Le Deley MC, Bergeron C, et al. Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high dose chemotherapy. Pediatr Blood Cancer . 2014;61:977-981.
  5. Bansal D, Totadri S, Chinnaswamy G, et al. Management of Neuroblastoma: ICMR Consensus Document. Indian J Pediatr. 2017;84:446-455 .
  6. Cai J, Pan C, Tang Y, et al. Multivariate analysis of risk factors for patients with stage 4 neuroblastoma who were older than 18 months at diagnosis: a report from a single institute in Shanghai, China.J Cancer Res Clin Oncol. 2017;143:1327-1335.
  7. Jain R, Hans R, Totadri S, et al. Autologous stem cell transplant for high-risk neuroblastoma: Achieving cure with low-cost adaptations. Pediatr Blood Cancer . 2020;67:e28273.
  8. Aksoylar S, Varan A, Vergin C, et al. Treatment of high-risk neuroblastoma: National protocol results of the Turkish Pediatric Oncology Group. J Cancer Res Ther. 2017;13:284-290.
  9. Bansal D, Marwaha RK, Trehan A, Rao KL, Gupta V. Profile and outcome of neuroblastoma with conventional chemotherapy in children older than one year: a 15 y experience. Indian Pediatr. 2008;45:135-139.
  10. Parikh NS, Howard SC, Chantada G, et al. International Society of Pediatric Oncology. SIOP-PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in low- and middle-income settings. Pediatr Blood Cancer.2015;62:1305-1316.
  11. Koshy A, Jain R, Srinivasan R, et al. Cytopathological spectrum of peripheral neuroblastic tumours in fine needle aspiration cytology and categorisation as per International Neuroblastoma Pathology Classification. Cytopathology. 2019;30:634-643.
  12. WHO Anthro (version 3.2.2) and macros. Geneva: WHO; 2011. http://www.who.int/childgrowth/software/en/. Accessed January 10, 2020.
  13. WHO AnthroPlus for Personal Computers: Software for Assessing Growth of the World’s Children and Adolescents. Geneva: WHO; 2009. http://www.who.int/growthref/tools/en/. Accessed January 12, 2020.
  14. WHO Global Database on Child Growth and Malnutrition. Geneva: WHO; 2016. http://www.who.int/nutgrowthdb/about/introduction/en/. Accessed January 12, 2020.
  15. High-risk neuroblastoma study 1 of SIOP-Europe (SIOPEN)/UK version/ August 2002/amended July 2007
  16. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466-1477.
  17. Kushner BH, Ostrovnaya I, Cheung IY, et al. Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.Oncotarget. 2016;7:4155-4166.
  18. Van Heerden J, Hendricks M, Geel J, et al. Overall survival for neuroblastoma in South Africa between 2000 and 2014. Pediatr Blood Cancer. 2019;66:e27944.
  19. Agarwala S, Mandelia A, Bakhshi S, et al. Neuroblastoma: outcome over a 14 y period from a tertiary care referral Center in India. J Pediatr Surg. 2014;49:1280-1285.
  20. Lau SCD, Unni MNM, Teh KH, et al. Autologous stem cell transplantation following high-dose chemotherapy in children with high-risk neuroblastoma: Practicality in resource-limited countries. Pediatr Blood Cancer . 2020;67:e28176.
  21. Radhakrishnan V, Raja A, Dhanushkodi M, Ganesan TS, Selvaluxmy G, Sagar TG. Real World Experience of Treating Neuroblastoma: Experience from a Tertiary Cancer Centre in India. Indian J Pediatr . 2019;86:417-426.
  22. Zhang YT, Chang J, Xu HM, Li YN, Zhong XD, Liu ZL. Treatment of Neuroblastoma with a Novel Delayed Intensification Chemotherapy. Indian J Pediatr . 2019;86:126-131.
  23. Cai J, Pan C, Tang Y, et al. Multivariate analysis of risk factors for patients with stage 4 neuroblastoma who were older than 18 months at diagnosis: a report from a single institute in Shanghai, China. J Cancer Res Clin Oncol . 2017;143:1327-1335.
  24. Mehdiabadi GB, Arab E, Rafsanjani KA, Ansari S, Moinzadeh AM. Neuroblastoma in Iran: an experience of 32 years at a referral childrens hospital. Asian Pac J Cancer Prev . 2013;14:2739-2742.
  25. Moussa E, Fawzy M, Younis A, et al. Combined Treatment Strategy and Outcome of High Risk Neuroblastoma: Experience of the Children’s Cancer Hospital-Egypt. Journal of Cancer Therapy . 2013;4:1435-1442.
  26. El-Sayed MI, Ali AM, Sayed HA, Zaky EM. Treatment results and prognostic factors of pediatric neuroblastoma: a retrospective study. Int Arch Med . 2010;3:37.
  27. Parise IZ, Haddad BR, Cavalli LR, et al. Neuroblastoma in southern Brazil: an 11-year study. J Pediatr Hematol Oncol . 2006;28:82-87.
  28. Pritchard J, Cotterill SJ, Germond SM, Imeson J, de Kraker J, Jones DR. High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group. Pediatr Blood Cancer . 2005;44:348-357.
  29. Berthold F, Boos J, Burdach S, et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol . 2005;6:649-658.
  30. Amoroso L, Erminio G, Makin G, et al. Topotecan-Vincristine-Doxorubicin in Stage 4 High-Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC: A SIOPEN Study. Cancer Res Treat . 2018;50:148-155.
  31. Elliott M, Gray J, Tweddle D, et al. Statement from CCLG Neuroblastoma SIG: Treatment and management of patients with high-risk neuroblastoma. March 2019. https://www.cclg.org.uk/write/MediaUploads/Member%20area/Treatment%20guidelines/HR_NB_-_March_2019.pdf.Accessed May 20, 2020.
  32. Park JR, Scott JR, Stewart CF, et al. Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children’s Oncology Group study. J Clin Oncol . 2011;29:4351-4357.
  33. Rujkijyanont P, Photia A, Traivaree C, et al. Clinical outcomes and prognostic factors to predict treatment response in high risk neuroblastoma patients receiving topotecan and cyclophosphamide containing induction regimen: a prospective multicenter study. BMC Cancer . 2019;19:961.
  34. Kretschmar CS, Kletzel M, Murray K, et al. Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: a pediatric oncology group study. J Clin Oncol . 2004;22:4119-4126.
  35. Garaventa A, Luksch R, Biasotti S, et al. A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma. Cancer . 2003;98:2488-2494.
  36. Pearson AD, Pinkerton CR, Lewis IJ, et al. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol . 2008;9:247-256.